Edesa Biotech Inc (EDSA)
NASDAQ:EDSA
EDSA Stock Chart & Stats
$1.48
>-$0.01(-0.02%)
At close: 4:00 PM EST
$1.48
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$0.72 - $9.37
Previous CloseN/A
Volume1.31K
Average Volume (3M)93.40K
Market Cap
$48.92M
Enterprise Value$36.87M
Total Cash (Recent Filing)$12.05M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.87
Next Earnings
May 08, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding8,348,161
10 Day Avg. Volume65,583
30 Day Avg. Volume93,401
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-362.80
Enterprise Value/Ebitda-4.74
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 3 Paridiprubart DataRobust Phase 3 efficacy and a placebo-comparable safety profile materially de-risks the lead program versus earlier-stage assets. Durable clinical validation across severity groups supports regulatory pathways, strengthens partnering/licensing prospects, and underpins commercial planning and payer discussions.
Low Leverage And Larger Equity BaseA conservatively levered balance sheet and a materially larger equity base improve financial flexibility during late-stage development. Reduced debt lowers refinancing risk and gives management more optionality to fund pivotal programs or negotiate non-dilutive partnerships over the medium term.
IP Filings And Manufacturing Scale-up SupportProvisional patents, government-funded trials, and manufacturing scale-up preparations strengthen commercialization readiness and protect market exclusivity. These structural initiatives increase partner attractiveness, lower time-to-market risk, and support a credible pathway from approval to supply.
Bears Say
No Revenue And Continued Net LossesAbsent commercial sales, the company remains dependent on clinical progress to generate revenue. Persistent net losses erode equity and mean the business cannot self-fund expansion or commercialization, keeping long-term viability contingent on successful approval and external financing.
Negative Operating And Free Cash FlowSustained cash burn tightly constrains runway and forces recurrent capital raises or partnerships. Negative operating and free cash flow limit internal investment in trials, commercialization, and scale-up, increasing dilution risk and creating pressure on execution over the coming 2-6 months.
Very Low Returns And Reliance On External CapitalDeeply negative ROE signals capital is not generating returns and heightens investor sensitivity to funding plans. Reliance on external capital raises execution risk, potential dilution, and could shift management focus toward short-term financing over longer-term commercial execution.
Edesa Biotech News
EDSA FAQ
What was Edesa Biotech Inc’s price range in the past 12 months?
Edesa Biotech Inc lowest stock price was $0.72 and its highest was $9.37 in the past 12 months.
What is Edesa Biotech Inc’s market cap?
Edesa Biotech Inc’s market cap is $48.92M.
When is Edesa Biotech Inc’s upcoming earnings report date?
Edesa Biotech Inc’s upcoming earnings report date is May 08, 2026 which is in 41 days.
How were Edesa Biotech Inc’s earnings last quarter?
Edesa Biotech Inc released its earnings results on Feb 13, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.525 by $0.245.
Is Edesa Biotech Inc overvalued?
According to Wall Street analysts Edesa Biotech Inc’s price is currently Overvalued.
Does Edesa Biotech Inc pay dividends?
Edesa Biotech Inc does not currently pay dividends.
What is Edesa Biotech Inc’s EPS estimate?
Edesa Biotech Inc’s EPS estimate is -0.26.
How many shares outstanding does Edesa Biotech Inc have?
Edesa Biotech Inc has 8,348,161 shares outstanding.
What happened to Edesa Biotech Inc’s price movement after its last earnings report?
Edesa Biotech Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.525. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Edesa Biotech Inc?
Currently, no hedge funds are holding shares in EDSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
EDSA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $232.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-42.51%
12-Months-Change
Fundamentals
Return on Equity
-55.75%
Trailing 12-Months
Asset Growth
253.26%
Trailing 12-Months
Company Description
Edesa Biotech Inc
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Technical Analysis
Eterna Therapeutics
―
Lipocine
―
XTL Biopharmaceuticals Sponsored ADR
―
Cocrystal Pharma
―
BioVie
―
Ownership Overview
18.86% Insiders
0.90% Mutual Funds
34.60% Other Institutional Investors
45.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---